Quantum Biopharma Ltd.
QNTM Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.5% and free cash flow grew 5.88%, each against the same quarter a year earlier.
Follow QNTM
Quantum Biopharma Ltd. (QNTM) EV/Sales
As of 16 October 2026, Quantum Biopharma Ltd. (QNTM) trades at a EV/Sales of 28.8×. Over the past ten years it has ranged from −33.8× (April 2021) to 2,323× (August 2024); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 140× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2019 | 140× | — |
| Sep 2019 | 0.0× | — |
| Jun 2019 | 0.0× | — |
| Mar 2019 | 0.0× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.3× |
| BYSI BeyondSpring Inc. compare | 13.8× |
| KYNB Kyntra Bio Inc compare | 16.3× |
| QNTM Quantum Biopharma Ltd. | 28.8× |
| CYAD Celyad SA compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)